Key insights
- Oracle's technology is supporting a large clinical trial in Africa, highlighting its growing presence in the healthcare sector. While not a major market mover, it reinforces Oracle's position in cloud-based clinical trial solutions and its expansion into emerging markets. The positive press and potential for growth in this area could contribute slightly to investor sentiment.
AUSTIN, Texas - The Africa Clinical Research Network has launched its first clinical trial using Oracle’s technology platform, according to a press release statement.
The PROTECT-Africa trial began in February and is being conducted in Zimbabwe, Rwanda, and Tanzania. The study aims to recruit 1,106 pregnant women to evaluate placental biomarkers for predicting severe pre-eclampsia-related outcomes in African women with hypertensive disorders of pregnancy.
ACRN selected Oracle Clinical One, Argus Safety, and analytics tools to manage the trial’s data and workflows. The organization has established an initial network of 59 sites across 14 African countries, including Senegal, The Gambia, Ghana, Nigeria, Kenya, Uganda, Ethiopia, Rwanda, Tanzania, Malawi, Botswana, South Africa, Zambia, and Zimbabwe.
Pre-eclampsia and related complications are a leading cause of maternal and fetal morbidity in resource-limited settings across Africa, according to the statement.
"Oracle’s robust and integrated clinical trial and safety solutions will enable us to conduct studies with greater efficiency, transparency, and, most importantly, an unwavering focus on patient well-being," said Tariro Makadzange, chief executive officer of ACRN.
The press release cited data indicating that less than three percent of global clinical trials are currently conducted in Africa. ACRN plans to launch additional clinical trials focused on global health this year.
Oracle (NYSE:ORCL) provides cloud-based clinical trial and safety solutions for pharmaceutical research and development. The software giant, with a market capitalization of $518.5 billion, reported revenue of $64.08 billion with 14.9% growth in the last twelve months. InvestingPro analysis indicates the stock is currently undervalued, with data showing Oracle as a prominent player in the Software industry maintaining strong profitability with a 67% gross profit margin. Investors can access detailed valuation analysis and 15 additional ProTips on InvestingPro.
In other recent news, Bloom Energy reported impressive first-quarter earnings, significantly surpassing Wall Street expectations. The company posted adjusted earnings per share of $0.44, which exceeded the analyst consensus of $0.13 by $0.31. Revenue reached $751.1 million, a 130% increase year-over-year, surpassing the analyst estimate of $530.41 million. This performance was driven by strong demand for its fuel cell technology among hyperscalers. Meanwhile, Oracle has expressed enthusiasm about its partnership with OpenAI, despite investor concerns about AI spending following reports of OpenAI missing key targets. Wedbush reiterated its Outperform rating for Oracle, citing high demand for OpenAI on both consumer and enterprise fronts. Additionally, Oracle NetSuite announced the launch of SuiteCloud Agent Skills, a set of AI coding agent tools aimed at assisting developers in building NetSuite customizations. Lastly, Goldman Sachs advised investors to favor hyperscalers over chipmakers in the AI infrastructure sector, highlighting skepticism about return on investment for hyperscalers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.